SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

04 Nov 2022 Evaluate
The sales for the September 2022 quarter moved down to Rs. 840.38 millions as compared to Rs. 1166.89 millions during the year-ago period.Net Profit for the quarter ended September 2022 dipped to Rs. 52.56  millions from Rs. 307.18 millions  in the corresponding previous quarter.Operating Profit reported a sharp decline to 104.82 millions from 368.33 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 840.38 1166.89 -27.98 1701.03 2243.39 -24.18 4278.11 2911.88 46.92
Other Income 15.49 25.96 -40.33 33.78 41.65 -18.90 105.06 50.98 106.08
PBIDT 104.82 368.33 -71.54 258.08 651.49 -60.39 1162.77 702.85 65.44
Interest 13.60 12.24 11.11 23.77 26.63 -10.74 48.32 42.07 14.86
PBDT 91.22 356.09 -74.38 234.31 624.86 -62.50 1114.45 660.78 68.66
Depreciation 23.08 20.57 12.20 46.41 39.55 17.35 81.80 67.30 21.55
PBT 68.14 335.52 -79.69 187.90 585.31 -67.90 1032.65 593.48 74.00
TAX 15.58 28.34 -45.02 50.34 38.57 30.52 72.79 79.89 -8.89
Deferred Tax 3.80 -27.07 -114.04 7.53 -58.54 -112.86 -107.29 -23.77 351.37
PAT 52.56 307.18 -82.89 137.56 546.74 -74.84 959.86 513.59 86.89
Equity 221.65 221.65 0.00 221.65 221.65 0.00 221.65 200.88 10.34
PBIDTM(%) 12.47 31.57 -60.49 15.17 29.04 -47.76 27.18 24.14 12.60

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×